Negative in Ames, in vitro chromosome aberration (human lymphocytes) and in vivo mouse micronucleus assays
“The genotoxic potential of AMX0035 was tested in a standard battery of in vitro (Ames, chromosomal aberration in human lymphocytes) and in vivo (micronucleus in CD-1 mouse) assays, which were adequate and negative.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Carcinogenicity
Not conducted; mouse and rat studies are postmarketing requirements
“Carcinogenicity studies have not been conducted. Carcinogenicity studies in mouse and rat may be conducted post-approval, as agreed to by the Division (Meeting Minutes, April 7, 2020, and July 22, 2021) because of the seriousness of the indication.”
✓ VerifiedFDA pharmacology/toxicology review, p. 6Source ↗
Reproductive & developmental
No adverse effects on maternal or offspring health and development in fertility, EFD or PPND studies
“There were no adverse effects on maternal health or offspring health and development in fertility, EFD, or PPND studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 47Source ↗
Safety pharmacology
No CNS study; minipig CV and rat respiratory studies showed no adverse effects
“CNS safety pharmacology was not assessed; however, cardiovascular and respiratory safety pharmacology endpoints were assessed in standalone studies in Gottingen minipig and SD rat, respectively, following administration of 1000 mg/kg PB/333.3 mg/kg TUDCA and did not indicate any adverse effects.”
✓ VerifiedFDA pharmacology/toxicology review, p. 45Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative